Therapeutics | Linker Strategy | Biological Evaluation | Special Remarks | References |
---|---|---|---|---|
Doxorubicin | Phenylacetyl hydrazone | MDA-MB-435 | Slightly improved activity and significantly reduced toxicity | Kratz et al., 2000 |
Maleimide spacer | MDA-MB-468 and LXFL 592; L292 | Amide or acid-sensitive link | Kratz et al., 1998a | |
Glutaraldehyde | K562 | Mechanistic studies | Lai et al., 1998 | |
HeLa | Bërczi et al., 1993a | |||
K562 | Sun et al., 1992 | |||
K562 | Barabas et al., 1992 | |||
H-Meso, HL60, Hep2 | Plasma membrane as the target | Barabas et al., 1991 | ||
NuGC4, SW403, tumor-bearing mice | More potent against resistant cell lines | Singh et al., 1998 | ||
KB-3-1, KB-8-5, KB-C1, KB-V1, MCF-7 | Prolong lifespan of the mice effectively against multidrug-resistant tumor cells | Fritzer et al., 1996 | ||
Resistant K562 | Conjugation to Ga2-Tf | Wang et al., 2000 | ||
K562, HL60 | Dose-dependent inhibition | Hatano et al., 1993 | ||
K562, HL60 | Inhibition of both cells | Bërczi et al., 1993b | ||
K562 | Enhanced cytotoxicity | Fritzer et al., 1992 | ||
Patients | Enhanced cytotoxicity | Sizensky et al., 1992 | ||
PHPMA | P388 | Conjugates kill the leukemia cell | Faulk et al., 1990 | |
Liposome-PEG | C6 glioma | Polymer conjugated, Tf-targeted | Št'astný et al., 1999 | |
Encapsulated in Tf-liposome-PEG | Eavarone et al., 2000 | |||
Toxin CRM107 | Thioether bond | scU87Mg, tumor-bearing mice | Effective in vitro but ineffective in vivo | Engebraaten et al., 2002 |
Rat-bearing U251MG | Chloroquine block the toxicity | Hagihara et al., 2000 | ||
Patients | Interstitial microinfusion | Laske et al., 1997 | ||
K562 and SNB75 | Cytosol translocation | Johnson et al., 1988 | ||
MMC | Glutaric anhydride spacer | HepG2 and cultured rat hepatocyte | Inhibited the growth of the HepG2 cell | Tanska et al., 2001 |
HL60 | TfR-mediated internalization | Tanska et al., 1998 | ||
Sarcoma 180 | Tanska et al., 1996 | |||
Daunorubicin | Glutaraldehyde | NCI-H69 (SCCL) | 10 times effective over free drug | Bejaoui et al., 1991 |
Insulin | Disulfide | Caco-2 and diabetic rat | A slow but prolonged hypoglycemic effect and dose-dependent | Xia et al., 2000 |
Cisplatin | Tf-PEG-liposome | MKN45P, tumor bearing mice | Increase drug level in tumor cells and higher animal survival rates | Iinuma et al., 2002 |
Chlorambucil | Maleimide spacer | MCF7, MOLT4 | Ester or acid-sensitive link, inhibit growth of tumor cells | Beyer et al., 1998 |
F(ab′)2 | Maleimide spacer | K562 | Acid-labile conjugates | Wellhöner et al., 1991 |
Ricin A | Disulfide | In vitro | Intracellular pathway | Kornfeld et al., 1991 |
α-IFN | Liposome-PLL | MBT2 | Tf-PLL promotes delivery and enhances antiproliferative activity | Liao et al., 1998 |
α-IFN, α-interferon; F(ab′)2, anti-tetanus fragments; MMC, mitomycin C.